Large Genetic Study Identifies New Prostate Cancer Loci
By LabMedica International staff writers Posted on 21 Sep 2014 |
Data obtained during a large genetic screening study have added 23 new genetic variants to the known loci linked to development of prostate cancer.
Collaborators from a number of international research institutes conducted a meta-analysis of more than 10 million single nucleotide polymorphisms (SNPs) in 43,303 prostate cancer cases and 43,737 controls from populations of European, African, Japanese, and Latino ancestry.
Results revealed 23 previously unknown loci associated with prostate cancer of which 15 variants were identified among men of European ancestry, seven were identified in multiancestry analyses, and one was associated with early-onset prostate cancer. These 23 variants, in combination with known prostate cancer risk variants, explain 33% of the familial risk for this disease in European-ancestry populations.
These findings indicate that for European men assessed for the 100 common variants, the 10% at highest risk are 2.9 times more likely than the average person to develop prostate cancer, while the top 1% of men is 5.7 times more likely to develop the disease.
Contributing author Dr. Rosalind Eeles, professor of oncogenetics at the Institute of Cancer Research (London, United Kingdom), said, "Our study tells us more about the effect of the genetic hand that men are dealt on their risk of prostate cancer. We know that there are a few major genes that are rare and significantly affect prostate cancer risk, but what we are now learning is that there are many other common genetic variants that individually have only a small effect on risk, but collectively can be very important. To use the playing cards analogy again, sometimes multiple low cards can combine to form a high risk score. We can now explain a third of the inherited risk of prostate cancer, and will shortly be conducting a clinical trial to find out whether testing for genetic variants in men can successfully pick up the disease early, and help direct targeted interventions for patients."
Related Links:
The Institute of Cancer Research
Collaborators from a number of international research institutes conducted a meta-analysis of more than 10 million single nucleotide polymorphisms (SNPs) in 43,303 prostate cancer cases and 43,737 controls from populations of European, African, Japanese, and Latino ancestry.
Results revealed 23 previously unknown loci associated with prostate cancer of which 15 variants were identified among men of European ancestry, seven were identified in multiancestry analyses, and one was associated with early-onset prostate cancer. These 23 variants, in combination with known prostate cancer risk variants, explain 33% of the familial risk for this disease in European-ancestry populations.
These findings indicate that for European men assessed for the 100 common variants, the 10% at highest risk are 2.9 times more likely than the average person to develop prostate cancer, while the top 1% of men is 5.7 times more likely to develop the disease.
Contributing author Dr. Rosalind Eeles, professor of oncogenetics at the Institute of Cancer Research (London, United Kingdom), said, "Our study tells us more about the effect of the genetic hand that men are dealt on their risk of prostate cancer. We know that there are a few major genes that are rare and significantly affect prostate cancer risk, but what we are now learning is that there are many other common genetic variants that individually have only a small effect on risk, but collectively can be very important. To use the playing cards analogy again, sometimes multiple low cards can combine to form a high risk score. We can now explain a third of the inherited risk of prostate cancer, and will shortly be conducting a clinical trial to find out whether testing for genetic variants in men can successfully pick up the disease early, and help direct targeted interventions for patients."
Related Links:
The Institute of Cancer Research
Latest Pathology News
- AI Integrated With Optical Imaging Technology Enables Rapid Intraoperative Diagnosis
- HPV Self-Collection Solution Improves Access to Cervical Cancer Testing
- Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues
- AI Advancements Enable Leap into 3D Pathology
- New Blood Test Device Modeled on Leeches to Help Diagnose Malaria
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities